Canada’s Pharmaceutical Data, Value and Access Think Tank
Canada’s Pharmaceutical Data, Value and Access Think Tank
By bringing together payers, patients, industry and Canadian health organizations, 20Sense facilitates data-driven and evidence-based healthcare decision-making, engineers pathways for more timely access to pharmaceutical innovation, and ensures appropriate value for payers and patients alike.
RWE+OBA Think Tank
20Sense collaborates with forward-thinking health system stakeholders to research and define Canadian best practices for building and implementing pathways and mechanisms, including the use of real-world evidence (RWE) and innovative outcomes-based agreements (OBAs) that support timely and equitable patient access to novel therapies.
RWE+OBA Think Tank 
PSP Think Tank
20Sense collaborates with Canadian stakeholders to study and advance patient support program (PSP) capabilities, best practices and standards that enable positive outcomes and access for patients, with a focus on continuous process improvement and evidence generation from PSP real-world data (RWD).
PSP Think Tank
The 20Sense Report
For the last decade, our quarterly publication has profiled the diverse voices across Canada’s pharmaceutical ecosystem and provided in-depth analysis on the trends shaping how Canadians access pharmaceutical innovations.
Read the report for free
Consultants and Researchers
20Sense advises health system stakeholders on ways to leverage data for improved healthcare decision-making, ensure appropriate value for Canadian payers and patients and improve access to pharmaceutical innovation.
Recent Publications
20Sense Report Issue 30: Integrating the Patient Voice into Healthcare Decisions
Webinar and panel discussion: The progress and possibilities of innovative payment models in Canada
Poster: Canadian Patient Support Program Enrolment Form Standardization